Neurological & Neurostimulation Devices: Global Regulation & Registration

For every regulator below we answer the three questions neurotech teams ask first: what class is my device, how long will it take, and what will it cost. Our pricing calculator turns those answers into a per-market estimate.

What are neurological and neurostimulation devices?

Neurostimulation devices, often grouped under the wider clinical term neuromodulation, treat neurological conditions by delivering controlled electrical, magnetic, or other signals to the brain, spinal cord, or peripheral nerves. Implantable systems like deep brain stimulation (DBS) for movement disorders, spinal cord stimulators (SCS) for chronic pain, vagus nerve and sacral nerve stimulators, and responsive neurostimulators for epilepsy sit at the high-risk end; external devices such as transcutaneous electrical nerve stimulation (TENS) units and non-invasive brain stimulation sit at the lower-risk end. Brain-computer interfaces (BCIs), which read neural signals to control software or prosthetics, are the newest members of the category.

Two distinctions drive everything that follows. First, neuromodulation is the umbrella; neurostimulation is the electrical subset most regulators write their rules around. Second, an external stimulator and an active implant are worlds apart in risk: the same broad technology can be a Class II device you clear in months or a Class III implant that takes years, and every jurisdiction draws the line a little differently. Every cost below therefore has two parts: the government fee, and our own flat annual service fee per market, from US$1,000 per year in the US (device listing and US Agent representation) and from US$2,000 per year in most other markets. Exact current figures live in our pricing calculator.

FDA neurostimulation device regulation (United States)

FDA regulates neurostimulation through its risk-based device framework, and the class gap is wide: most implanted stimulators are among the most heavily regulated devices FDA oversees, while external stimulators clear on a far lighter path.

• Classification. Implanted active neurostimulators, including deep brain stimulation systems, spinal cord stimulators, and responsive neurostimulators, are generally Class III and require a PMA supported by clinical evidence. External devices such as TENS units and many peripheral nerve stimulators are Class II via 510(k). Genuinely novel low- or moderate-risk devices without a predicate take the De Novo route, often with Breakthrough Device designation, but novel high-risk implants, including implanted brain-computer interfaces, follow the IDE-to-PMA Class III route instead. Devices for a small neurological population can also use the Humanitarian Device Exemption (HDE): deep brain stimulation for dystonia and for OCD were both approved this way.
• Timeline. A 510(k) for a Class II external device typically runs 3 to 9 months including preparation; a Class III PMA is a multi-year program, typically 1 to 3 years with the clinical study on the critical path. A Pre-Submission meeting is worth the few weeks it adds, and Breakthrough designation brings interactive review that can compress the path for eligible devices.
• Cost. Government fees: US$26,067 for a standard 510(k) review (US$6,517 for qualified small businesses) plus US$11,423 per year in establishment registration; a PMA carries a substantially higher FDA user fee. Our flat US$1,000 per year covers FDA establishment registration and device listing maintenance plus US Agent representation; 510(k) preparation and submission are scoped as a separate project.

Start from our United States market page for the full FDA pathway.

Brain-computer interfaces (BCIs): the FDA's newest neurological pathway

A brain-computer interface reads neural activity and translates it into commands for a computer, prosthetic, or communication device, most often for patients with paralysis, ALS, or amputation. Lower-risk, non-invasive BCIs, such as EEG-based stroke-rehabilitation systems like Neurolutions' IpsiHand, have been classified via De Novo into Class II with special controls. Permanently implanted BCIs for paralysis, ALS, or amputation are high-risk devices: they undergo IDE clinical investigations, frequently under Breakthrough Device designation, and are expected to reach market via a Class III PMA, with Synchron building toward the first such PMA filing. FDA has published dedicated guidance on implanted BCI devices to steer the nonclinical and clinical evidence expected. Long-term safety, biocompatibility, and, because a BCI is a connected implant running software, cybersecurity documentation are all central to the submission. We build the classification rationale, the Pre-Submission strategy, and the evidence plan a first-of-kind BCI needs.

EU MDR neurostimulation and active-implant classification (CE marking)

Under the EU Medical Device Regulation, neurostimulation devices are split sharply by whether they are implanted, and a notified body sits in the middle of every timeline above Class I.

• Classification. Active implantable neurostimulators, including DBS, spinal cord, vagus nerve, and sacral nerve systems and formerly governed by the Active Implantable Medical Devices Directive, are Class III, the highest risk class under MDR. External stimulators such as TENS are typically Class IIa. Non-invasive brain stimulation, though, is not treated like TENS: equipment for transcranial brain stimulation that applies electrical currents or magnetic or electromagnetic fields penetrating the cranium to modify neuronal activity, where it has no intended medical purpose, is a Class III Annex XVI product under Commission Implementing Regulation (EU) 2022/2347 (in force since 22 December 2022), with common specifications in (EU) 2022/2346. Medical-purpose transcranial stimulation devices such as rTMS and tES are classified under the standard MDR active-device rules and need their own classification analysis rather than defaulting to the Class IIa/TENS route. Where a BCI uses AI, the EU AI Act adds obligations on top of MDR.
• Timeline. Plan 12 to 24 months for a first Class III certification, driven by clinical evaluation depth and notified body capacity; a Class IIa external device is materially faster. Building MDR-grade clinical documentation, not the review itself, is usually the long pole. Novel Class III implantables also pass through the MDR Article 54 expert-panel clinical evaluation consultation, which the notified body triggers and which should be built into first-certification timelines.
• Cost. There is no central government fee; the money goes to the notified body, and a first Class III conformity assessment runs above the EUR 30,000 to 70,000 range typical of a Class IIa cycle, plus annual surveillance, on top of the cost of building clinical evidence. Our EU Authorized Representative service is a flat annual fee from US$2,000, capped at US$4,000 as your portfolio grows, and covers EC REP representation, document review, and EUDAMED support; CE-marking work with your notified body is scoped separately.

Notified body strategy should shape your EU plan early; see the European Union market page for the MDR route.

Neurostimulation device registration in Brazil and Latin America (ANVISA RDC 751)

Brazil anchors any Latin American strategy, classifying devices under RDC 751 on the IMDRF model, and Mexico's COFEPRIS is the region's second gate. Both require a local representative; we act as Brazil Registration Holder without taking control of your registration.

• Classification. RDC 751 uses four risk classes. Active implantable neurostimulators land in Class III or IV and require full registro with a complete technical dossier and, in most cases, international B-GMP certification; lower-risk external stimulators can use the streamlined notificacao route.
• Timeline. Class III-IV registration typically plans for 6 to 12 months, longer when a GMP certification is on the critical path; notification for lower-risk devices is a matter of weeks. Mexico's COFEPRIS runs 6 to 12 months, faster where reliance on an FDA or CE approval applies.
• Cost. ANVISA government fees: R$1,406 to notify a Class I-II product; Class III-IV family registration runs R$8,510-19,856, plus a one-time international B-GMP certification of R$72,805 where required. COFEPRIS charges MX$16,499-30,798 per product by class. Our registration service starts at US$2,000 per year, US$3,000 for high-risk classes, in both markets.

Start with the Brazil market page; labeling, instructions for use, and submissions are prepared natively in Portuguese and Spanish.

Neurostimulation device registration in Asia-Pacific: Singapore first, then ASEAN

Most overseas neurotech teams enter Asia-Pacific through Singapore: HSA works in English, follows the IMDRF model, and rewards a strong FDA or CE dossier with a fast abridged review. A Singapore approval then anchors expansion across ASEAN, through Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, where reliance-friendly frameworks make each additional market incremental. Japan and Korea are the region's big mature prizes with their own systems and languages, and China is the largest market but the hardest entry, with local type testing, clinical review for implants, and the longest timelines, so treat it as its own program rather than a default stop.

• Classification. Singapore's HSA uses risk classes A through D; implanted neurostimulators are Class D, since all active implantable devices take Singapore's highest class, with external devices lower, and ASEAN members track the same IMDRF-style model. Japan classifies against JMDN codes with PMDA approval (shonin) for high-risk implants; Korea's MFDS uses Classes I-IV; China places active implants in Class III, its highest.
• Timeline. With a reference approval, HSA abridged evaluation targets 160 to 220 working days for Class C-D implants, roughly 7 to 10 months, with faster expedited routes (120 to 180 working days) for eligible devices; ASEAN registrations typically run 3 to 9 months per market on the same dossier. Japan plans 9 to 14 months (longer for novel implants), Korea 6 to 12 months including KGMP, and China 12 to 24 months or more including type testing and clinical review.
• Cost. Singapore's government fees are light: a SGD 560 application plus SGD 2,010-6,250 evaluation by class, and ASEAN peers are similar (Malaysia MYR 500-3,750; Thailand THB 3,100-74,000). Japan's PMDA review fees range from under JPY 0.5 million for generic devices to roughly JPY 5.6-16.4 million for improved and new high-risk devices; China's NMPA first-registration fee for an imported Class III device is roughly RMB 310,000 (about RMB 210,000 for imported Class II), before type testing. Our Singapore and ASEAN registration service starts at US$2,000 per year (US$3,000 for high-risk classes); China, Japan, and Korea are quoted flat per market on the same model.

One well-built reference dossier does most of the region's work. See the Singapore, Malaysia, Thailand, Japan, South Korea, and China market pages.

Neurostimulation device registration in Saudi Arabia and MENA (SFDA)

The Gulf is one of the fastest-growing regions in our portfolio, and its regulators are built around reliance: a strong FDA or CE approval does most of the work if the dossier is assembled correctly. SFDA regulates neurostimulation devices explicitly and requires a local Authorized Representative.

• Classification. SFDA classifies devices into risk classes A through D on the IMDRF model and, for most neurostimulation devices, mirrors your reference-market class; active implants sit at the top of the scale. The UAE's MOHAP and other MENA authorities lean on the reference approval's classification.
• Timeline. With an FDA or CE approval in hand, SFDA marketing authorization (MDMA) typically closes in 2 to 6 months, and UAE registration runs a similar range. Without a reference approval, expect materially longer, especially for high-risk implants.
• Cost. Government fees across the Gulf are modest, generally a few thousand US dollars' equivalent per authority, so the real spend is dossier assembly, Arabic labeling where required, and local representation. We quote MENA registration programs flat per market, on the same transparent model as our calculator markets.

See the Saudi Arabia and UAE market pages; we cover the wider region under one program.

Evidence, quality system, and lifecycle

Active implants carry the heaviest evidence burden of almost any device type, and neurostimulation is no exception. We build ISO 13485 and FDA QMSR quality systems, then plan the clinical investigations, biocompatibility testing (ISO 10993), electrical safety and EMC testing (IEC 60601 for the external console and programmer, with the ISO 14708 series - 14708-1 general and 14708-3 for implantable neurostimulators - governing the implant itself), and MR-safety evaluation and labeling - the MR Conditional versus MR Unsafe determination marked per ASTM F2503 and supported by the RF-induced heating (F2182), displacement (F2052), torque (F2213), and image-artifact (F2119) test methods and FDA's MR-environment labeling guidance - that FDA, EU MDR, and Asia-Pacific reviewers expect, designing the evidence once so it carries across markets. For connected stimulators and brain-computer interfaces we maintain cybersecurity documentation aligned with FDA, EU MDR, and IEC 81001-5-1. After launch, vigilance reporting, field-safety corrective actions, and change assessments keep every registration current.

One program, every major market

A global neurotech program is a sequencing problem: pick the anchor market, generate the clinical and technical evidence once, and reuse classification analyses, evidence, and QMS artifacts everywhere else. We run the full program from a single team, covering strategy, submissions, in-country representation, and post-market maintenance, with transparent government fees and timelines in our pricing calculator.